{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:07Z","timestamp":1792089427721,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["97005843"],"award-info":[{"award-number":["97005843"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Enzybiotics are promising alternatives to conventional antibiotics for drug-resistant infections. Exolysins, as a class of enzybiotics, show antibacterial effects against methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA). This study evaluated a novel exolysin containing an SH3b domain for its antibacterial activity against MRSA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study designed a chimeric exolysin by fusing the Cell-binding domain (SH3b) from Lysostaphin with the lytic domain (LYZ2) from the gp61 enzyme. Subsequently, LYZ2-SH3b was cloned and expressed in\n                      <jats:italic>Escherichia coli (E. coli).<\/jats:italic>\n                      Finally, the antibacterial effects of LYZ2-SH3b compared with LYZ2 and vancomycin against reference and clinical isolates of MRSA were measured using the disc diffusion method, the minimal inhibitory concentration (MIC), and the minimal bactericidal concentration (MBC) assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of bioinformatics showed that LYZ2-SH3b was stable, soluble, and non-allergenic. Protein purification was performed with a 0.8\u00a0mg\/ml yield for LYZ2-SH3b. The plate lysis assay results indicated that, at the same concentrations, LYZ2-SH3b has a more inhibitory effect than LYZ2. The MICs of LYZ2 were 4\u00a0\u00b5g\/mL (ATCC 43,300) and 8\u00a0\u00b5g\/mL (clinical isolate ST239), whereas, for LYZ2-SH3b, they were 2\u00a0\u00b5g\/mL (ATCC 43,300) and 4\u00a0\u00b5g\/mL (clinical isolate ST239). This suggests a higher efficiency of LYZ2-SH3b compared to LYZ2. Furthermore, the MBCs of LYZ2 were 4\u00a0\u00b5g\/mL (ATCC 43,300) and 8\u00a0\u00b5g\/mL (clinical isolate ST239), whereas, for LYZ2-SH3b, they were 2\u00a0\u00b5g\/mL (ATCC 43,300) and 4\u00a0\u00b5g\/mL (clinical isolate ST239), thus confirming the superior lytic activity of LYZ2-SH3b over LYZ2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study suggests that phage endolysins, such as LYZ2-SH3b, may represent a promising new approach to treating MRSA infections, particularly in cases where antibiotic resistance is a concern. But further studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12866-023-03002-9","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:01:41Z","timestamp":1694592101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["LYZ2-SH3b as a novel and efficient enzybiotic against methicillin-resistant Staphylococcus aureus"],"prefix":"10.1186","volume":"23","author":[{"given":"Marzieh","family":"Asadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mortaza","family":"Taheri-Anganeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed Hossein","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Maleksabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Mostafavi-Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolkhalegh","family":"Keshavarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Savardashtaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"3002_CR1","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez D, Fern\u00e1ndez L, Rodr\u00edguez A, Garc\u00eda P. Are phage lytic proteins the Secret Weapon to kill Staphylococcus aureus? mBio. 2018;9(1):e01923\u201317.","DOI":"10.1128\/mBio.01923-17"},{"key":"3002_CR2","doi-asserted-by":"publisher","first-page":"668430","DOI":"10.3389\/fcimb.2021.668430","volume":"11","author":"Y Lu","year":"2021","unstructured":"Lu Y, Wang Y, Wang J, Zhao Y, Zhong Q, Li G, et al. Phage endolysin LysP108 showed promising antibacterial potential against methicillin-resistant Staphylococcus aureus. Front Cell Infect Microbiol. 2021;11:668430.","journal-title":"Front Cell Infect Microbiol"},{"key":"3002_CR3","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez D, Rodr\u00edguez-Rubio L, Ruas-Madiedo P, Fern\u00e1ndez L, Campelo AB, Briers Y et al. Design and selection of engineered lytic proteins with Staphylococcus aureus decolonizing activity. Front Microbiol. 2021;12.","DOI":"10.3389\/fmicb.2021.723834"},{"issue":"1","key":"3002_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/antibiotics9010032","volume":"9","author":"E Meade","year":"2020","unstructured":"Meade E, Slattery MA, Garvey M. Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: resistance is futile? Antibiotics. 2020;9(1):32.","journal-title":"Antibiotics"},{"issue":"12","key":"3002_CR5","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.3390\/v4123316","volume":"4","author":"M Deghorain","year":"2012","unstructured":"Deghorain M, Van Melderen L. The Staphylococci phages family: an overview. Viruses. 2012;4(12):3316\u201335.","journal-title":"Viruses"},{"key":"3002_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.micres.2016.04.008","volume":"191","author":"AC Rios","year":"2016","unstructured":"Rios AC, Moutinho CG, Pinto FC, Del Fiol FS, Jozala A, Chaud MV, et al. Alternatives to overcoming bacterial resistances: state-of-the-art. Microbiol Res. 2016;191:51\u201380.","journal-title":"Microbiol Res"},{"issue":"3","key":"3002_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/v9030050","volume":"9","author":"J Doss","year":"2017","unstructured":"Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N. A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms. Viruses. 2017;9(3):50.","journal-title":"Viruses"},{"issue":"6","key":"3002_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/antibiotics10060722","volume":"10","author":"S Arroyo-Moreno","year":"2021","unstructured":"Arroyo-Moreno S, Begley M, Dembicka K, Coffey A. Engineering of the CHAPk staphylococcal phage endolysin to enhance antibacterial activity against stationary-phase cells. Antibiotics. 2021;10(6):722.","journal-title":"Antibiotics"},{"issue":"8","key":"3002_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/antibiotics9080519","volume":"9","author":"L Vacek","year":"2020","unstructured":"Vacek L, Kobzov\u00e1 \u00c5, \u010cmel\u00edk R, Pant\u016f\u010dek R, Janda L. Enzybiotics LYSSTAPH-S and LYSDERM-S as potential therapeutic agents for chronic MRSA Wound Infections. Antibiotics. 2020;9(8):519.","journal-title":"Antibiotics"},{"key":"3002_CR10","doi-asserted-by":"crossref","unstructured":"R\u00f6hrig C, Huemer M, Lorg\u00e9 D, Luterbacher S, Phothaworn P, Schefer C et al. Targeting hidden pathogens: cell-penetrating enzybiotics eradicate intracellular drug-resistant staphylococcus aureus. mBio. 2020;11(2).","DOI":"10.1128\/mBio.00209-20"},{"key":"3002_CR11","doi-asserted-by":"crossref","unstructured":"Muharram MM, Abulhamd AT, Aldawsari MF, Alqarni MH, Labrou NE. Development of staphylococcus enzybiotics: the ph28 gene of staphylococcus epidermidis phage ph15 is a two-domain endolysin. Antibiotics. 2020;9(4).","DOI":"10.3390\/antibiotics9040148"},{"issue":"4","key":"3002_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11262-020-01762-4","volume":"56","author":"J Kaur","year":"2020","unstructured":"Kaur J, Singh P, Sharma D, Harjai K, Chhibber S. A potent enzybiotic against methicillin-resistant Staphylococcus aureus. Virus Genes. 2020;56(4):480\u201397.","journal-title":"Virus Genes"},{"issue":"6","key":"3002_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/v10060284","volume":"10","author":"B Son","year":"2018","unstructured":"Son B, Kong M, Ryu S. The Auxiliary Role of the Amidase Domain in Cell Wall binding and exolytic activity of staphylococcal phage endolysins. Viruses. 2018;10(6):284.","journal-title":"Viruses"},{"issue":"1","key":"3002_CR14","first-page":"36","volume":"6","author":"G Rahimzadeh","year":"2018","unstructured":"Rahimzadeh G, Gill P, Rezai MS. Endolysins of bacteriophages as an anti-methicillin resistant staphylococcus aureus infection in children: a narrative review. J Pediatr Rev. 2018;6(1):36\u201343.","journal-title":"J Pediatr Rev"},{"issue":"2","key":"3002_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/antibiotics7020029","volume":"7","author":"C S\u00e3o-Jos\u00e9","year":"2018","unstructured":"S\u00e3o-Jos\u00e9 C. Engineering of phage-derived lytic enzymes: improving their potential as antimicrobials. Antibiotics. 2018;7(2):29.","journal-title":"Antibiotics"},{"issue":"1","key":"3002_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1574-6968.2008.01152.x","volume":"284","author":"M Rashel","year":"2008","unstructured":"Rashel M, Uchiyama J, Takemura I, Hoshiba H, Ujihara T, Takatsuji H, et al. Tail-associated structural protein gp61 of Staphylococcus aureus phage \u03a6MR11 has bifunctional lytic activity. FEMS Microbiol Lett. 2008;284(1):9\u201316.","journal-title":"FEMS Microbiol Lett"},{"key":"3002_CR17","first-page":"00888","volume":"AAC","author":"K-i Okuda","year":"2013","unstructured":"Okuda K-i, Zendo T, Sugimoto S, Iwase T, Tajima A, Yamada S, et al. Effects of bacteriocins on methicillin-resistant Staphylococcus aureus biofilm. Antimicrob Agents Chemother. 2013;AAC:00888\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"3002_CR18","doi-asserted-by":"publisher","first-page":"615887","DOI":"10.3389\/fmicb.2020.615887","volume":"11","author":"B Son","year":"2021","unstructured":"Son B, Kong M, Lee Y, Ryu S. Development of a novel chimeric endolysin, Lys109 with enhanced lytic activity against Staphylococcus aureus. Front Microbiol. 2021;11:615887.","journal-title":"Front Microbiol"},{"issue":"4","key":"3002_CR19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/v13040680","volume":"13","author":"E Murray","year":"2021","unstructured":"Murray E, Draper LA, Ross RP, Hill C. The advantages and challenges of using endolysins in a clinical setting. Viruses. 2021;13(4):680.","journal-title":"Viruses"},{"key":"3002_CR20","doi-asserted-by":"crossref","unstructured":"Kashani HH, Schmelcher M, Sabzalipoor H, Hosseini ES, Moniri R. Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies. Clin Microbiol Rev. 2018;31(1).","DOI":"10.1128\/CMR.00071-17"},{"issue":"3","key":"3002_CR21","doi-asserted-by":"publisher","first-page":"e1062590","DOI":"10.1080\/21597081.2015.1062590","volume":"5","author":"DR Roach","year":"2015","unstructured":"Roach DR, Donovan DM. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage. 2015;5(3):e1062590.","journal-title":"Bacteriophage"},{"key":"3002_CR22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fmicb.2014.00542","volume":"5","author":"H Yang","year":"2014","unstructured":"Yang H, Yu J, Wei H. Engineered bacteriophage lysins as novel anti-infectives. Front Microbiol. 2014;5:542.","journal-title":"Front Microbiol"},{"issue":"1","key":"3002_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41589-019-0393-4","volume":"16","author":"LS Gonzalez-Delgado","year":"2020","unstructured":"Gonzalez-Delgado LS, Walters-Morgan H, Salamaga B, Robertson AJ, Hounslow AM, Jagielska E, et al. Two-site recognition of Staphylococcus aureus peptidoglycan by lysostaphin SH3b. Nat Chem Biol. 2020;16(1):24\u201330.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"3002_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-42435-z","volume":"9","author":"P Mitkowski","year":"2019","unstructured":"Mitkowski P, Jagielska E, Nowak E, Bujnicki JM, Stefaniak F, Niedzia\u0142ek D, et al. Structural bases of peptidoglycan recognition by lysostaphin SH3b domain. Sci Rep. 2019;9(1):1\u201314.","journal-title":"Sci Rep"},{"key":"3002_CR25","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Rubio L, Mart\u00ednez B, Rodr\u00edguez A, Donovan DM, Garc\u00eda P. Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 HydH5 virion associated peptidoglycan hydrolase: fusions, deletions and synergy with LysH5. Applied and environmental microbiology. 2012:AEM. 07621-11.","DOI":"10.1128\/AEM.07621-11"},{"issue":"1","key":"3002_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1471-2180-11-226","volume":"11","author":"VD Paul","year":"2011","unstructured":"Paul VD, Rajagopalan SS, Sundarrajan S, George SE, Asrani JY, Pillai R, et al. A novel bacteriophage Tail-Associated Muralytic enzyme (TAME) from phage K and its development into a potent antistaphylococcal protein. BMC Microbiol. 2011;11(1):226.","journal-title":"BMC Microbiol"},{"issue":"1","key":"3002_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femsle\/fnu019","volume":"362","author":"SC Becker","year":"2015","unstructured":"Becker SC, Swift S, Korobova O, Schischkova N, Kopylov P, Donovan DM, et al. Lytic activity of the staphylolytic twort phage endolysin CHAP domain is enhanced by the SH3b cell wall binding domain. FEMS Microbiol Lett. 2015;362(1):1.","journal-title":"FEMS Microbiol Lett"},{"key":"3002_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jare.2019.10.005","volume":"21","author":"Y Cong","year":"2020","unstructured":"Cong Y, Yang S, Rao X. Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features. J Adv Res. 2020;21:169\u201376.","journal-title":"J Adv Res"},{"issue":"1","key":"3002_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41522-021-00208-5","volume":"7","author":"AC Duarte","year":"2021","unstructured":"Duarte AC, Fern\u00e1ndez L, De Maesschalck V, Guti\u00e9rrez D, Campelo AB, Briers Y, et al. Synergistic action of phage phiIPLA-RODI and lytic protein CHAPSH3b: a combination strategy to target Staphylococcus aureus biofilms. npj Biofilms and Microbiomes. 2021;7(1):1\u201310.","journal-title":"npj Biofilms and Microbiomes"},{"key":"3002_CR30","doi-asserted-by":"crossref","unstructured":"Murray E, Draper LA, Ross RP, Hill C. The Advantages and Challenges of using endolysins in a clinical setting. Viruses. 2021;13(4).","DOI":"10.3390\/v13040680"},{"key":"3002_CR31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fcimb.2017.00290","volume":"7","author":"H Haddad Kashani","year":"2017","unstructured":"Haddad Kashani H, Fahimi H, Dasteh Goli Y, Moniri R. A novel chimeric endolysin with antibacterial activity against methicillin-resistant Staphylococcus aureus. Front Cell Infect Microbiol. 2017;7:290.","journal-title":"Front Cell Infect Microbiol"},{"key":"3002_CR32","volume-title":"Methods for Dilution Antimicrobial susceptibility tests for Bacteria that grow aerobically; approved Standard. CLSI document M07-A9. 9","author":"FR Cockerill","year":"2012","unstructured":"Cockerill FR, Wikler M, Alder J, Dudley M, Eliopoulos G, Ferraro M, et al. Methods for Dilution Antimicrobial susceptibility tests for Bacteria that grow aerobically; approved Standard. CLSI document M07-A9. 9. Pennsylvania, PA, USA: CLSI (Clinical and Laboratory Standard Institute); 2012."},{"issue":"8","key":"3002_CR33","doi-asserted-by":"publisher","first-page":"e0182821","DOI":"10.1371\/journal.pone.0182821","volume":"12","author":"H Mohammad","year":"2017","unstructured":"Mohammad H, Younis W, Ezzat HG, Peters CE, AbdelKhalek A, Cooper B, et al. Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus. PLoS ONE. 2017;12(8):e0182821.","journal-title":"PLoS ONE"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-03002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-023-03002-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-03002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T20:11:53Z","timestamp":1700338313000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-023-03002-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3002"],"URL":"https:\/\/doi.org\/10.1186\/s12866-023-03002-9","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"12 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"257"}}